Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.20 USD
Change Today +0.0031 / 1.58%
Volume 980.9K
HEB On Other Exchanges
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

hemispherx biopharma inc (HEB) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/13/14 - $0.40
52 Week Low
07/2/15 - $0.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hemispherx biopharma inc (HEB) Related Bloomberg News

View More Bloomberg News

hemispherx biopharma inc (HEB) Related Businessweek News

No Related Businessweek News Found

hemispherx biopharma inc (HEB) Details

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company’s primary products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; and Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts. It is also developing Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

37 Employees
Last Reported Date: 03/19/15
Founded in 1990

hemispherx biopharma inc (HEB) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.9M
Executive Vice Chairman, Chief Financial Offi...
Total Annual Compensation: $1.3M
Chief Medical Officer and Medical Director
Total Annual Compensation: $336.8K
Compensation as of Fiscal Year 2014.

hemispherx biopharma inc (HEB) Key Developments

Hemispherx Biopharma, Inc. Amends Restated and Amended By-Laws

On June 23, 2015, the Board of Hemispherx Biopharma, Inc. amended restated and amended By-Laws in accordance with a directive of Board of Directors to reduce the quorum, solely for the 2015 annual meeting of stockholders, from holders of a majority in voting power of the outstanding shares of stock to the holders of 40% in voting power of the outstanding shares of stock. The Board reduced the quorum, after consultation with the company's proxy advisory firm and due to low voter turnout experienced in the past.

Hemispherx Biopharma, Inc. Announces Preliminary Approval of Securities Class Action Settlement

Hemispherx Biopharma announced that the United States District Court for the Eastern District of Pennsylvania has granted preliminary approval of a settlement of the currently pending securities class action, Frater versus Hemispherx Biopharma, Inc. A final settlement hearing has been scheduled for July 22, 2015. The settlement will be paid from the company's insurance coverage and will not result in the payment of any funds by the company. The settlement expressly is not an admission of culpability by Hemispherx or any of the individual defendants.

Hemispherx Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

Hemispherx Biopharma, Inc. reported earnings results for the first quarter ended March 31, 2015. For the quarter, total revenues were $36,000, compared to $76,000 for the same quarter ended March 31, 2014. Operating loss was $4.92 million, compared to an operating loss of $5.11 million for the same quarter ended March 31, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.20 USD +0.0031

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $307.51 USD +0.60
AstraZeneca PLC 4,167 GBp -23.00
Baxter International Inc $38.30 USD -0.56
Medigene AG €10.33 EUR +0.358
Sarepta Therapeutics Inc $30.14 USD +0.39
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 270.8x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 186.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at